The 9th China International Import Expo opened on Nov. 5 at the National Exhibition and Convention Center in Shanghai, with the medical equipment and healthcare zone drawing steady crowds. Unlike previous editions, where multinationals focused on showing products already launched overseas under the theme of “exhibits becoming products,” this year “China premiere” and “China synchronized” have become buzzwords in the zone, with several multinational drug and device companies positioning China as the global launch market for innovative products.
This year’s CIIE drew exhibitors from 162 countries, regions and international organizations, including 4,142 overseas companies, with exhibition space exceeding 440,000 square meters for the first time. More than 480 representative exhibits made global debuts, Asian premieres or China debuts — a record. The medical zone gathered 12 Fortune Global 500 pharmaceutical companies, as well as the world’s top three medical imaging companies and top three radiotherapy equipment makers.
In surgical robotics, Fosun Pharma is exhibiting for the ninth consecutive year, with this year marking the 20th anniversary of the da Vinci surgical robot’s entry into China. Intuitive Fosun brought the next-generation multi-port surgical robot da Vinci 5 for its first public showing in China; the product has not yet been approved in China and features more than 150 design innovations, roughly 10,000 times the computing power of its predecessor, and a new force-feedback technology. In February, da Vinci 5 entered the National Medical Products Administration’s “green channel” for innovative medical devices. Also on display were the da Vinci SP single-port surgical system, an upgraded Ion version shown in China for the first time, and the da Vinci Xi, which is now produced locally.
Intuitive Surgical CEO and Intuitive Fosun Chairman Gary Lo said at a Nov. 6 product briefing that this year’s lineup is “the most complete portfolio of innovative products in China to date.” As of the end of September, da Vinci systems in China had served more than 1 million patient cases, with cumulative installations of da Vinci and Ion systems in China exceeding 520 units. Intuitive Fosun has established 28 da Vinci training centers and five Ion training centers, training more than 23,000 medical professionals.
Fosun Pharma’s exhibits reflect a dual “bringing in” and “going out” approach. On imported products, the phosphate-absorption inhibitor Velphoro, which had its China debut at the 7th CIIE in 2024, was approved in February 2025 and entered China’s national medical insurance catalog at the end of that year. China’s first CAR-T therapy, Yikaida, has built more than 190 treatment centers across 29 provincial-level regions, treating more than 1,500 patients with relapsed or refractory lymphoma. On self-developed products, the PD-1 inhibitor Hansizhuang and the trastuzumab biosimilar Hanquyou have both been approved in more than 50 countries and regions.
Novo Nordisk brought 17 innovative drugs and four innovative injection devices this year, including six innovative drugs making their China or global debuts. NovoGrow, the world’s first approved once-weekly basal insulin/GLP-1RA formulation, had its global premiere at this year’s CIIE, with China as its first country of commercial launch worldwide; Chinese patients began using the drug in July, earlier than in Novo Nordisk’s home country of Denmark, and the global Phase III trial was led by a Chinese expert as principal investigator. On the weight-management pipeline, the oral semaglutide tablet NovoWin had its China premiere; the drug launched in the U.S. in January and has surpassed 8 million prescriptions, and its China marketing application was accepted in August. The injectable version of NovoWin was approved in China in September for the MASH indication.
Novo Nordisk global CEO Mike Doustdar said the company is paying increasing attention to innovation from China and incorporating it into its R&D pipeline. At the end of September, Novo Nordisk reached a licensing agreement with China’s Hengrui Pharma for the GLP-1/GIP dual receptor agonist HRS-1596, with a $300 million upfront payment and a potential total of up to $2.6 billion. China is Novo Nordisk’s second-largest market globally, with cumulative investment in China of about 18 billion yuan (approximately $2.7 billion) since 2003.
Novartis is exhibiting for the ninth time this year under the theme “See the Unseen,” with the immunology drug candidate Ianalumab shown in China for the first time. Data provided by Novartis shows that since 2022, its development of new drugs and new indications in China has been 100% synchronized with the globe, and starting this year, new-drug and new-indication registration applications in China are also 100% synchronized globally. Gao Rong, head of Novartis’s China drug development unit, said China is becoming the global launch market for Novartis’s breakthrough therapies. The company also announced strengthened R&D in China, with its three R&D centers in Shanghai, Beijing and Suzhou advancing early-stage clinical research.
Medtronic’s exhibition scale and premiere lineup this year are its largest ever, bringing more than 120 products and solutions, with Chairman and CEO Geoff Martha visiting the CIIE for the first time. Among seven debut products, the globally premiered Kanghui orthopedic surgical navigation and positioning system was independently developed by a Chinese team; the brain-computer interface closed-loop system BrainSense aDBS had its Asia-Pacific premiere, and the MiniMed 780G hybrid closed-loop insulin delivery system had its China premiere. Medtronic also set up a dedicated co-innovation zone, inviting four Chinese local companies — Ronovo, HeartCare, Pulse Medical and Rossum Robot — to exhibit, and announced it is preparing a Medtronic China Phase III fund.
Yingkang Life, the big-health brand under Haier Group, is exhibiting for the seventh year, this year occupying a prime spot in the medical zone with more than 40 innovations and a debut rate above 60%. Its life sciences segment showed the DreamFlow·E sample aliquoting, extraction and purification workstation, whose process flow is generated and validated by AI; in biopharmaceuticals, Shanghai RAAS, which it exhibited, has completed enrollment for the Phase III trial of its self-developed first-in-class hemophilia-targeted drug SR604 for preventing bleeding episodes in hemophilia A/B. Yingkang Life this year released a “1+3+X” AI strategy, and its “Xiaoying” agent platform has developed more than 450 AI-native applications.
Other multinational drugmakers also stepped up launches. AstraZeneca’s booth spans about 1,000 square meters, showcasing nearly 50 innovative drugs, with Bazedoxifene tablets and Golimumab making their China debuts. Sanofi brought three “world-first” products — Anxu, Xingshuping and Ruidapu. Gilead is exhibiting for the fifth consecutive year, highlighting the long-acting HIV capsid inhibitor lenacapavir and the rare-disease drug seladelpar. Merck & Co. showcased about 30 innovative drugs already approved in China and expects to introduce more than 50 new products and new indications to China over the next five years. First-time exhibitor Pierre Fabre built a 500-square-meter booth, bringing products including the BRAF inhibitor Braftovi.
The medical zone this year also reflected two major trends: AI-enabled precision diagnosis and treatment, and a focus on chronic diseases and autoimmune conditions. A Medtronic executive in charge of the neuromodulation business said BrainSense aDBS, based on an algorithmic model, can automatically match and adjust electrical stimulation parameters according to changes in a patient’s neurological state; it is currently in clinical trials at several leading Chinese top-tier hospitals, with about 100 patients planned for enrollment and completion expected as early as 2027. Intuitive Fosun’s digital Intuitive platform uses AI to assist surgical operations, and its algorithms have accumulated hundreds of thousands of surgical cases for model training.
In chronic diseases, Pfizer brought the global premiere of its next-generation biased GLP-1 receptor agonist ecnoglutide; Eli Lilly’s world’s only oral small-molecule GLP-1 drug made its CIIE debut, with a marketing application for weight management and type 2 diabetes already submitted to the National Medical Products Administration. In autoimmune diseases, Novartis’s marketing application for a drug targeting Sjögren’s syndrome was accepted by the NMPA in February; Roche brought Gazyva, the first anti-CD20 monoclonal antibody to show a complete renal response benefit in a randomized Phase III study in lupus nephritis.
Across nine editions of the CIIE, the story multinational drug and device companies tell at the expo has clearly shifted: from selling mature overseas products in China to doing R&D in China and launching first in China. NovoGrow launching in China before Denmark, Novartis’s registration applications fully synchronized with the globe, and Medtronic holding a world premiere for a product developed by its Chinese team all confirm this change.